scholarly article | Q13442814 |
review article | Q7318358 |
P50 | author | Pieter E Postmus | Q56826661 |
P2093 | author name string | Splinter TA | |
Smit EF | |||
Groen HJ | |||
Ebels T | |||
P2860 | cites work | p53-dependent apoptosis modulates the cytotoxicity of anticancer agents | Q29615031 |
Cell cycle control and cancer | Q29617536 | ||
C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. | Q34124421 | ||
Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus | Q34253429 | ||
Angiogenin antagonists prevent tumor growth in vivo | Q34767203 | ||
p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein | Q35433948 | ||
p53 function and dysfunction | Q35721291 | ||
Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers | Q35795148 | ||
Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia | Q35798342 | ||
c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. | Q35833390 | ||
Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up | Q35978377 | ||
Prevention of metastasis by inhibition of the urokinase receptor | Q36332391 | ||
The cellular functions of small GTP-binding proteins | Q37821945 | ||
Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas | Q38480548 | ||
A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. | Q38481941 | ||
Prognostic significance of the expression ofras oncogene product in non-small cell lung cancer | Q38488364 | ||
Ploidy as a prognostic determinant in surgically treated lung cancer | Q38491981 | ||
Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population | Q39510056 | ||
Lectin cytochemistry and histochemistry | Q39659822 | ||
Molecular and biological factors in the prognosis of non-small cell lung cancer | Q40376628 | ||
Current approaches to targeting cancer using antiangiogenesis therapies | Q40394125 | ||
The implications of angiogenesis for the biology and therapy of cancer metastasis | Q40394139 | ||
Tumour vasculature--a potential therapeutic target | Q40403280 | ||
Implications of the p53 tumor-suppressor gene in clinical oncology. | Q40500755 | ||
Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung | Q40518313 | ||
Prognostic factors in lung cancer: tables and comments | Q40632618 | ||
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis | Q40694250 | ||
Apoptosis in cancer therapy: crossing the threshold | Q40694262 | ||
How loops, beta sheets, and alpha helices help us to understand p53. | Q40694267 | ||
The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. | Q40722479 | ||
Three distinct regions involved in 3p deletion in human lung cancer | Q41123112 | ||
Expression of Blood-Group Antigen A — A Favorable Prognostic Factor in Non-Small-Cell Lung Cancer | Q41153716 | ||
A specific cell surface glycoconjugate controlling cell motility: evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis | Q41688146 | ||
p185neu expression in human lung adenocarcinomas predicts shortened survival | Q41725055 | ||
A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. | Q42283680 | ||
p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas | Q42491451 | ||
bcl-2 protein in non-small-cell lung carcinoma | Q42508274 | ||
Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes | Q42804780 | ||
Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer | Q43795364 | ||
Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer | Q43982323 | ||
Accumulation of p53 protein correlates with a poor prognosis in human lung cancer | Q44896147 | ||
Correlation of Expression of H/LeY/LeBAntigens with Survival in Patients with Carcinoma of the Lung | Q44983634 | ||
Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer | Q45258587 | ||
Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small-cell lung cancer | Q45744672 | ||
Survival after resection of stage II non-small cell lung cancer | Q46482962 | ||
p53 in non-small-cell lung cancer. | Q52883628 | ||
Inhibitors of carbohydrate processing: A new class of anticancer agents. | Q53461334 | ||
Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. | Q53467456 | ||
Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. | Q53529803 | ||
Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma | Q58454772 | ||
Membrane proteases in focus | Q59052655 | ||
Relation of neovascularisation to metastasis of non-small-cell lung cancer | Q59219829 | ||
Prognostic significance of flow cytometry in lung cancer. A 5-year study | Q62352440 | ||
Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer | Q67503401 | ||
Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study | Q67507451 | ||
Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients | Q67542458 | ||
Deletions of 17p and p53 mutations in preneoplastic lesions of the lung | Q67904409 | ||
Relationship between tumor DNA ploidy and regional lymph node changes in lung cancer | Q68078343 | ||
Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung | Q68082107 | ||
ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis | Q68119388 | ||
ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent | Q68254101 | ||
Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer | Q68259992 | ||
K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung | Q68532141 | ||
Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer | Q69373028 | ||
Diameter, cell type, and survival in stage I primary non-small-cell lung cancer | Q69821205 | ||
The percentage of aneuploid cells is significantly correlated with survival in accurately staged patients with stage 1 resected squamous cell lung cancer and long-term follow up | Q69935929 | ||
Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma | Q70138207 | ||
Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients | Q70472514 | ||
Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct | Q70646171 | ||
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1 | Q71644976 | ||
p53: a glimpse at the puppet behind the shadow play | Q72041259 | ||
Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer | Q72071261 | ||
Frequency and Distribution of Occult Micrometastases in Lymph Nodes of Patients With Non-Small-Cell Lung Carcinoma | Q72072302 | ||
Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model | Q72198415 | ||
Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma | Q72365281 | ||
Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease | Q72395994 | ||
Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma | Q72611044 | ||
c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties | Q72680125 | ||
Cooperative tumorigenic effects of germline mutations in Rb and p53 | Q72781894 | ||
Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer | Q72940056 | ||
Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group | Q72946735 | ||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 638-646 | |
P577 | publication date | 1996-06-01 | |
P1433 | published in | Thorax | Q7796158 |
P1476 | title | New prognostic factors in resectable non-small cell lung cancer | |
P478 | volume | 51 |
Q61910329 | Absence of microsatellite instability in breast carcinomas with both p53 and c-erbB-2 alterations |
Q74423639 | Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer |
Q41648540 | Biology of pulmonary preneoplastic lesions. |
Q58416209 | Blood vessel invasion in resected non small cell lung carcinomas is predictive of metastatic occurrence |
Q37062357 | Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial |
Q57763264 | Does the use of immunohistochemistry to identify micrometastases provide useful information in the staging of node-negative non-small cell lung carcinomas? |
Q44618341 | Expression of HER2 and C-KIT in Nasopharyngeal Carcinoma: Implications for a New Therapeutic Approach |
Q33588251 | Genetics and pulmonary medicine. 7. Somatic mutations in the development of lung cancer |
Q79745353 | Prognostic factors |
Q73198378 | Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer |
Search more.